239 related articles for article (PubMed ID: 31691490)
61. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
62. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer.
Xiong F; Wu C; Chang J; Yu D; Xu B; Yuan P; Zhai K; Xu J; Tan W; Lin D
Cancer Res; 2011 Aug; 71(15):5175-81. PubMed ID: 21676885
[TBL] [Abstract][Full Text] [Related]
63. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
64. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
[TBL] [Abstract][Full Text] [Related]
65. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
66. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
67. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
[TBL] [Abstract][Full Text] [Related]
68. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract][Full Text] [Related]
69. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
Han JY; Lee YS; Shin ES; Hwang JA; Nam S; Hong SH; Ghang HY; Kim JY; Yoon SJ; Lee JS
Pharmacogenomics J; 2014 Feb; 14(1):20-7. PubMed ID: 23478653
[TBL] [Abstract][Full Text] [Related]
70. The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.
He M; Liu S; Gallolu Kankanamalage S; Borromeo MD; Girard L; Gazdar AF; Minna JD; Johnson JE; Cobb MH
Transl Oncol; 2018 Apr; 11(2):292-299. PubMed ID: 29413762
[TBL] [Abstract][Full Text] [Related]
71. Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome.
Lee JH; Yoo SS; Hong MJ; Choi JE; Kim S; Kang HG; Do SK; Kim JH; Baek SA; Lee WK; Do Yoo J; Choi SH; Lee YH; Seo H; Lee J; Lee SY; Cha SI; Kim CH; Park JY
Sci Rep; 2021 Jan; 11(1):1794. PubMed ID: 33469055
[TBL] [Abstract][Full Text] [Related]
72. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
[TBL] [Abstract][Full Text] [Related]
73. Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.
Saruwatari K; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ohe Y; Goto K
Clin Lung Cancer; 2016 Nov; 17(6):581-587. PubMed ID: 27424806
[TBL] [Abstract][Full Text] [Related]
74. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
75. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
[TBL] [Abstract][Full Text] [Related]
76. High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
Lyu Q; Zhu W; Wei T; Ding W; Cao M; Wang Q; Guo L; Luo P; Zhang J
Cancer Med; 2021 Nov; 10(21):7863-7876. PubMed ID: 34564955
[TBL] [Abstract][Full Text] [Related]
77. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
[TBL] [Abstract][Full Text] [Related]
78. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
79. Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer.
Chen C; Zhu YH; Huang JA
J Cancer Res Ther; 2018 Jun; 14(Supplement):S336-S340. PubMed ID: 29970686
[TBL] [Abstract][Full Text] [Related]
80. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
